[The efficacy of the Zirtek (cetirizine) preparation in chronic recurrent urticaria and seasonal allergic rhinitis].

Clinical trials of a new histamine H1-blocker of the III generation zyrtec (cetirizine) manufactured in Belgium (UCB) demonstrated its high efficacy in pollenosis and chronic idiopathic urticaria. The drug has the advantage of a rapid absorption (a marked antihistamine effect occurs 2 hours upon administration), the action duration (24 hours), convenient regimen (once a day), the absence of CNS effects such as sleepiness, ow attention, reduced memory and discoordinated movements.